Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019

Safiri, Saeid; Pourfathi, Hojjat; Eagan, Arielle Wilder; Mansournia, Mohammad Alì; Khodayari, Mohammad Taghi; Sullman, Mark J.M.; Kaufman, Jay S.; Collins, Gary S.; Dai, Hancheng; Bragazzi, Nicola Luigi; Kolahi, Ali‐Asghar

doi:10.1097/j.pain.0000000000002275

Cited by 152 publications

(113 citation statements)

References 43 publications

Supporting

Mentioning

107

Contrasting

Unclassified

Order By: Relevance

“…Globally, migraine was the second largest contributor to the disability-adjusted life-years (DALYs) lost due to neurological disorders in 2016, accounting for 16.3% [95% uncertainty interval (UI): 11.7–20.8] of the attributable DALYs ( 6 ). The global age-standardized prevalence of migraine increased by 1.7% (0.7–2.8) from 1990 to 2019, and in 2019 there were 1.1 billion (0.98–1.3) prevalent cases and 525.5 (78.8–1,194) years lived with disability (YLDs) per 100,000 population ( 7 ). In the United States, the economic burden of migraine was significantly higher in patients with migraine, than among those without migraine ($11,010 vs. $4,436; p < 0.01) ( 8 ).…”

Section: Introductionmentioning

confidence: 99%

Migraine: A Review on Its History, Global Epidemiology, Risk Factors, and Comorbidities

et al. 2022

Self Cite

View full text Add to dashboard Cite

Migraine affects more than one billion individuals each year across the world, and is one of the most common neurologic disorders, with a high prevalence and morbidity, especially among young adults and females. Migraine is associated with a wide range of comorbidities, which range from stress and sleep disturbances to suicide. The complex and largely unclear mechanisms of migraine development have resulted in the proposal of various social and biological risk factors, such as hormonal imbalances, genetic and epigenetic influences, as well as cardiovascular, neurological, and autoimmune diseases. This review presents a comprehensive review of the most up-to-date literature on the epidemiology, and risk factors, as well as highlighting the gaps in our knowledge.

show abstract

Section: Introductionmentioning

confidence: 99%

Migraine: A Review on Its History, Global Epidemiology, Risk Factors, and Comorbidities

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“… 2 In the United States (US), overall prevalence of migraine (2019 estimate) was 16.7%. 3 Each year, migraine occurs in 12% of the US population, disproportionately affecting approximately 18% of women versus 6% of men. 4…”

Section: Introductionmentioning

confidence: 99%

Treatment Patterns for Calcitonin Gene-Related Peptide Monoclonal Antibodies Including Galcanezumab versus Conventional Preventive Treatments for Migraine: A Retrospective US Claims Study

Varnado¹,

Manjelievskaia²,

Ye³

et al. 2022

PPA

View full text Add to dashboard Cite

Background Most conventional, oral, preventive treatments for migraine are non-specific and ~50% of patients discontinue them within six months. In 2018, the Food and Drug Administration approved three preventive migraine treatments: monoclonal antibodies (mAb) targeting the calcitonin gene-related peptide (CGRP) pathway implicated in migraine; galcanezumab and fremanezumab which target CGRP ligand; and erenumab which targets CGRP receptor. Real-world treatment patterns for CGRP mAb are limited. Purpose To compare real-world treatment patterns for CGRP mAb, specifically galcanezumab versus standard-of-care (SOC) migraine preventive treatments. Patients and methods This retrospective, observational study included 12-month baseline and 6- and 12-month follow-up analyses using IBM ® MarketScan ® databases. Patients identified were aged ≥18 years with ≥1 claim (first claim=index) for CGRP mAb (erenumab, fremanezumab, or galcanezumab) or SOC preventives (eg, antiepileptics, beta-blockers, antidepressants, or onabotulinumtoxinA) as index drugs between May/01/2018 and June/30/2019. Propensity score matching was used to address confounding by observed covariates. Outcomes analyzed included proportion of days covered (PDC), persistence (≤60-day gap), and first non-index drug switch. Descriptive, chi-square (categorical), and t -test (continuous) analyses were conducted. Results The study included 3082 (CGRP mAb versus SOC) and 421 (galcanezumab versus SOC) matched patient pairs with 12-month follow-up. Mean age across cohorts ranged 43.2–44.4 years (females: 85.7–88.6%). Compared with SOC, the CGRP mAb cohort had higher mean persistence (212.5 vs 131.9 days), adherence (PDC: 55.1% vs 35.2%), and more patients were adherent with PDC ≥80% (32.7% vs 18.7%) (all p <0.001). During 12-month follow-up, fewer patients discontinued CGRP mAb versus SOC (58.8% vs 77.6%, p <0.001). Galcanezumab versus SOC comparisons yielded similar results. In the CGRP mAb cohort, most switchers (28.3%) used galcanezumab as subsequent treatment. Largely similar results were observed for 6-month follow-up cohorts. Conclusion Patients on CGRP mAb and specifically galcanezumab showed higher adherence and persistence than patients on SOC migraine preventive treatments.

show abstract

“…In the GBD 2019, 369 diseases and injuries were studied in 204 countries and territories and 21 regions from 1990 to 2019 [10]. The general methodology for estimating the burden of diseases for GBD 2019 have been described in detail in previous studies [10,13,14]. Detailed descriptions of the methods are presented in the Additional file 1.…”

Section: Overviewmentioning

confidence: 99%

The global burden and trends of maternal sepsis and other maternal infections in 204 countries and territories from 1990 to 2019

Chen¹,

Wang

Gao³

et al. 2021

BMC Infect Dis

View full text Add to dashboard Cite

Background Maternal sepsis and other maternal infections (MSMI) have considerable impacts on women’s and neonatal health, but data on the global burden and trends of MSMI are limited. Comprehensive knowledge of the burden and trend patterns of MSMI is important to allocate resources, facilitate the establishment of tailored prevention strategies and implement effective clinical treatment measures. Methods Based on data from the Global Burden of Disease database, we analysed the global burden of MSMI by the incidence, death, disability-adjusted life year (DALY) and maternal mortality ratio (MMR) in the last 30 years. Then, the trends of MSMI were assessed by the estimated annual percentage change (EAPC) of MMR as well as the age-standardized rate (ASR) of incidence, death and DALY. Moreover, we determined the effect of sociodemographic index (SDI) on MSMI epidemiological parameters. Results Although incident cases almost stabilized from 1990 to 2015, the ASR of incidence, death, DALY and MMR steadily decreased globally from 1990 to 2019. The burden of MSMI was the highest in the low SDI region with the fastest downward trends. MSMI is still one of the most important causes of maternal death in the developed world. Substantial diversity of disease burden and trends occurred in different regions and individual countries, most of which had reduced burden and downward trends. The MMR and ASR were negatively correlated with corresponding SDI value in 2019 in 204 countries/territories and 21 regions. Conclusion These findings highlight significant improvement in MSMI care in the past three decades, particularly in the low and low-middle SDI regions. However, the increased burden and upward trends of MSMI in a few countries and regions are raising concern, which poses a serious challenge to maternal health. More tailored prevention measures and additional resources for maternal health are urgently needed to resolve this problem.

show abstract

Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019

Cited by 152 publications

References 43 publications

Migraine: A Review on Its History, Global Epidemiology, Risk Factors, and Comorbidities

Migraine: A Review on Its History, Global Epidemiology, Risk Factors, and Comorbidities

Treatment Patterns for Calcitonin Gene-Related Peptide Monoclonal Antibodies Including Galcanezumab versus Conventional Preventive Treatments for Migraine: A Retrospective US Claims Study

The global burden and trends of maternal sepsis and other maternal infections in 204 countries and territories from 1990 to 2019

Contact Info

Product

Resources

About